On March 30, 2026, Glucotrack, Inc. (NASDAQ: GCTK) announced its financial results for the year ended December 31, 2025, highlighting significant advancements in its continuous blood glucose monitoring technology. The company reported a net loss of $19.4 million for 2025, an improvement from the $22.6 million loss in 2024. This reduction in losses is attributed to non-cash losses recognized in the previous year related to debt settlements and warrant issuances. Glucotrack's cash and cash equivalents increased to $7.4 million, up from $5.6 million in 2024, bolstered by a $4.0 million private placement completed in December 2025. The company is preparing to file an Investigational Device Exemption (IDE) with the FDA, aiming to launch a U.S. clinical trial for its novel continuous blood glucose monitoring (CBGM) technology in the second half of 2026. The recent issuance of three new patents further strengthens Glucotrack's intellectual property portfolio, positioning it favorably in the competitive landscape of diabetes management technologies. CEO Paul V. Goode emphasized the company's momentum and reinforced balance sheet as it approaches critical development and regulatory milestones. The financial results and strategic outlook suggest a cautiously optimistic future for Glucotrack, with potential for growth as it advances its innovative solutions for diabetes care.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.